Alternatives

Life Sciences

Our Life Sciences team’s domain expertise, deep network, and advisory capabilities position us to identify the next generation of leading therapeutics, tools, and diagnostics companies.
wwd-life-sciences_21-9_1840x788.jpg
At a Glance
$650
MillionCapital Raised
25
YearsAverage Experience of Investment Committee
6
Investment Themes

Source: Goldman Sachs Asset Management. As December 31, 2024

What Makes Us Different

Sourcing

We operate a robust, multi-channel sourcing engine that leverages Goldman Sachs’ relationships across academic and medical institutions, corporates, venture capital and private equity firms, and company founders and executives.

Capital Formation

We believe that many life sciences companies would benefit from scaling privately, but a funding gap has historically forced these companies to go public too early. By better aligning investment capital with company innovation, we hope to drive better outcomes for companies and, ultimately, patients.

Value Creation

We partner with companies to enhance and accelerate value creation by helping them establish the right business and financial strategies, execute, and achieve strong exits.

Investments
All12
Precision Medicine6
Immunotherapy5
Scalable Platform1
Precision Medicine
Biotechnology company focused on discovering and developing small molecule precision medicines by targeting cancer-associated mutations that have historically been challenging to drug.
Immunotherapy
Clinical-stage biotechnology company focused on developing novel biologics-based treatments for cancers.
Precision Medicine
Biopharmaceutical company focused on discovering the next generation of precision medicines by targeting molecular machines that underlie human disease.
Precision Medicine
Precision neuroscience biotechnology company developing small molecule therapeutics to address significant unmet needs in neurological disorders.
Precision Medicine
Biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer.
Precision Medicine
Clinical stage biotechnology company focused on developing next-generation oral medicines for hematologic cancers.
Immunotherapy
Biotechnology company creating best-in-class novel biologics for patients suffering from a range of diseases in immunology and inflammation.
Immunotherapy
Biotechnology company developing best-in-class multifunctional antibodies for oncology and immune-mediated diseases.
Immunotherapy
Clinical stage biotechnology company developing multivalent vaccines against life-threatening respiratory viruses.
Immunotherapy
Biotechnology company pioneering development of genetics-informed novel biologics against inflammatory & immunological disorders.
Scalable Platform
Clinical stage biotechnology company advancing novel neuropsychiatric medicines based on clinically validated mechanisms powered by their Glyph™ platform.
Precision Medicine
Clinical stage biotechnology company developing innovative first- and best-in-class therapies for neuropsychiatric disorders.

Source: Goldman Sachs Asset Management as of February 14, 2025. Investments were selected to highlight the largest investments made as of February 14, 2025. We believe these selected case studies should be considered as a reflection of our investment process, and references to these particular assets/portfolio companies should not be considered a recommendation of any particular security, investment, or portfolio company.  Any mention of an investment decision is intended only to illustrate our investment strategy and is not indicative of the performance of our strategy as a whole. It should not be assumed that any investment decisions shown will prove to be profitable or any future investment decisions will be profitable or equal the performance of the investments discussed herein. The holdings and/or allocations shown may not represent all of the strategy’s investments. Please contact your Goldman Sachs Asset Management representative to obtain the holdings presented above as well as each holding’s contribution to performance and a complete list of past recommendations. Please see additional disclosures in the appendix.

Innovation Themes

Precision Medicine

Precision medicine is the ability to deliver medicines that target a patient’s underlying cause of disease based on their genetics or other unique biological characteristics.

Genetic Medicine

Genetic medicine is the ability to alter a patient’s gene expression to treat disease through the introduction or alteration of genetic material.

Cell Therapy

Cell therapy is the ability to use specific, genetically-engineered cells to combat disease or regenerate tissue.

Artificial Intelligence/Machine Learning

Machine learning is the ability to use advanced computation to understand complex biology and design potential therapeutics.

Immunotherapy

Immunotherapy is the ability to engage and manipulate the immune system as an approach to treating disease.

Synthetic Biology

Synthetic biology is the redesign of living systems for useful purposes, including medicines.

Source: Goldman Sachs Asset Management. As of December 31, 2024. This information discusses general market activity, industry or sector trends, or other broad-based economic, market or political conditions and should not be construed as research or investment advice. This material has been prepared by Goldman Sachs and is not financial research nor a product of Goldman Sachs Global Investment Research (GIR). It was not prepared in compliance with applicable provisions of law designed to promote the independence of financial analysis and is not subject to a prohibition on trading following the distribution of financial research. The views and opinions expressed may differ from those of Goldman Sachs Global Investment Research or other departments or divisions of Goldman Sachs and its affiliates. Investors are urged to consult with their financial advisors before buying or selling any securities. This information may not be current and Goldman Sachs has no obligation to provide any updates or changes.

Our Leadership Team
Our team comprises experienced life sciences investors with deep domain expertise across disciplines.
Avatar
Amit Sinha
Head of Life Sciences Investing
Avatar
Colin Walsh
Managing Director
Avatar
Josh Richardson
Managing Director
Advisory Board
Our investment team is complemented by an industry leading Advisory Board comprised of academics, clinicians, scientific experts, and entrepreneurs.
Avatar
Lloyd Minor
Dean, Stanford University School of Medicine
Avatar
Diane Mathis
Morton Grove-Rasmussen Chair of Immunohematology, Harvard Medical School
Avatar
David Chang
CEO, Allogene
Avatar
Ross Levine
Deputy Physician-in-Chief and Translational Research, Memorial Sloan Kettering
Avatar
Anima Anandkumar
Bren Professor of Computing and Mathematical Sciences of the California Institute of Technology and Senior Director of AI Research at NVIDIA
Avatar
Sean Nolan
Biotech Executive
Avatar
Ryan Watts
CEO, Denali Therapeutics
Start the Conversation
Contact Goldman Sachs Asset Management for a detailed discussion of your needs.
card-poster